%0
Generic
%T
Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival
%A Becker, Cornelia
%A Krahl, Rainer
%A Schulze, Antje
%A Maschmeyer, Georg
%A Junghanß, Christian
%A Franke, Astrid
%A Peter, Norma
%A Haenel, Mathias
%A Wedding, Ulrich
%A Wolf, Hans-Heinrich
%A Haehling, Detlev
%A Meran, Johannes
%A Doelken, Gottfried
%A Kaempfe, Dietrich
%A Kettner, Erika
%A Grobe, Norbert
%A Florschuetz, Axel
%A Kreibich, Ute
%A Schirmer, Veronika
%A Ittel, Thomas
%A Schulze, Mathias
%A Huhn, Renate
%A Zschuppe, Ernst
%A Opitz, Bernd
%A Assmann, Michael
%A Hasenclever, Dirk
%A Poenisch, Wolfram
%A Helbig, Werner
%A Niederwieser, Dietger W.
%I American Society of Hematology
%@ 0006-4971
%@ 1528-0020
%K Cell Biology
%K Hematology
%K Immunology
%K Biochemistry
%D 2008
%C American Society of Hematology
%U http://slubdd.de/katalog?TN_libero_mab2